CTAP(TFA? (103429-32-9 free base)
Code | Size | Price |
---|
TAR-TP2050L-1mg | 1mg | £235.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP2050L-5mg | 5mg | £483.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP2050L-10mg | 10mg | £667.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP2050L-25mg | 25mg | £994.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP2050L-50mg | 50mg | £1,315.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TP2050L-100mg | 100mg | £1,741.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
CTAP TFA is a potent, highly selective, and brain penetrant antagonist of μ-opioid receptor with IC50 of 3.5 nM. It displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID)
CAS:
TP2050L
Formula:
C53H70F3N13O13S2
Molecular Weight:
1218.33
Pathway:
Endocrinology/Hormones; GPCR/G Protein; Neuroscience
Purity:
0.9962
SMILES:
CC(O)C1C(NC(C(NC(C(N)=O)C(O)C)=O)C(C)(C)SSCC(NC(C(N)CC2=CC=CC=C2)=O)C(NC(CC3=CC=C(O)C=C3)C(NC(CC4=CNC5=CC=CC=C54)C(NC(CCC/N=C(N)N)C(N1)=O)=O)=O)=O)=O.O=C(O)C(F)(F)F
Target:
Opioid Receptor
References
Mitchell J Bartlett, et al. Highly-selective ?-opioid Receptor Antagonism Does Not Block L-DOPA-induced Dyskinesia in a Rodent Model.BMC Res Notes